Immunopeptidomic Data Integration to Artificial Neural Networks Enhances Protein-Drug Immunogenicity Prediction

Recombinant DNA technology has, in the last decades, contributed to a vast expansion of the use of protein drugs as pharmaceutical agents. However, such biological drugs can lead to the formation of anti-drug antibodies (ADAs) that may result in adverse effects, including allergic reactions and compromised therapeutic efficacy. Production of ADAs is most often associated with activation of CD4 T cell responses resulting from proteolysis of the biotherapeutic and loading of drug-specific peptides into major histocompatibility complex (MHC) class II on professional antigen-presenting cells. Recently, readouts from MHC-associated peptide proteomics (MAPPs) assays have been shown to correlate with the presence of CD4 T cell epitopes. However, the limited sensitivity of MAPPs challenges its use as an immunogenicity biomarker. In this work, MAPPs data was used to construct an artificial neural network (ANN) model for MHC class II antigen presentation. Using Infliximab and Rituximab as showcase stories, the model demonstrated an unprecedented performance for predicting MAPPs and CD4 T cell epitopes in the context of protein-drug immunogenicity, complementing results from MAPPs assays and outperforming conventional prediction models trained on binding affinity data.

[1]  Hans-Georg Rammensee,et al.  MHC ligands and peptide motifs: first listing , 2004, Immunogenetics.

[2]  S. Vermeire,et al.  Immunogenicity of infliximab: how to handle the problem? , 2007, Acta gastro-enterologica Belgica.

[3]  Morten Nielsen,et al.  Quantitative Predictions of Peptide Binding to Any HLA-DR Molecule of Known Sequence: NetMHCIIpan , 2008, PLoS Comput. Biol..

[4]  Tatiana A. Tatusova,et al.  NCBI Reference Sequences: current status, policy and new initiatives , 2008, Nucleic Acids Res..

[5]  Søren Buus,et al.  Functional recombinant MHC class II molecules and high-throughput peptide-binding assays , 2009, Immunome research.

[6]  O. Lund,et al.  NetMHCIIpan-2.0 - Improved pan-specific HLA-DR predictions using a novel concurrent alignment and weight optimization training procedure , 2010, Immunome research.

[7]  Morten Nielsen,et al.  NNAlign: A Web-Based Prediction Method Allowing Non-Expert End-User Discovery of Sequence Motifs in Quantitative Peptide Data , 2011, PloS one.

[8]  Morten Nielsen,et al.  Seq2Logo: a method for construction and visualization of amino acid binding motifs and sequence profiles including sequence weighting, pseudo counts and two-sided representation of amino acid enrichment and depletion , 2012, Nucleic Acids Res..

[9]  O. Lund,et al.  NetMHCIIpan-3.0, a common pan-specific MHC class II prediction method including all three human MHC class II isotypes, HLA-DR, HLA-DP and HLA-DQ , 2013, Immunogenetics.

[10]  Ian Kimber,et al.  Immunogenicity of therapeutic proteins: Influence of aggregation , 2013, Journal of immunotoxicology.

[11]  Marie-Claude Djidja,et al.  Aggregation of Human Recombinant Monoclonal Antibodies Influences the Capacity of Dendritic Cells to Stimulate Adaptive T-Cell Responses In Vitro , 2014, PloS one.

[12]  P. Roche,et al.  The ins and outs of MHC class II-mediated antigen processing and presentation , 2015, Nature Reviews Immunology.

[13]  Alessandro Sette,et al.  An open-source computational and data resource to analyze digital maps of immunopeptidomes , 2015, eLife.

[14]  F. Kolbinger,et al.  Secukinumab, a novel anti–IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity , 2016, mAbs.

[15]  David Gfeller,et al.  Unsupervised HLA Peptidome Deconvolution Improves Ligand Prediction Accuracy and Predicts Cooperative Effects in Peptide–HLA Interactions , 2016, The Journal of Immunology.

[16]  Morten Nielsen,et al.  NNAlign: a platform to construct and evaluate artificial neural network models of receptor–ligand interactions , 2017, Nucleic Acids Res..

[17]  Jennifer G. Abelin,et al.  Mass Spectrometry Profiling of HLA‐Associated Peptidomes in Mono‐allelic Cells Enables More Accurate Epitope Prediction , 2017, Immunity.

[18]  Ruedi Aebersold,et al.  A Case for a Human Immuno‐Peptidome Project Consortium , 2017, Immunity.

[19]  J. Kalden,et al.  Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment , 2017, Nature Reviews Rheumatology.

[20]  M. Nielsen,et al.  NetMHCpan-4.0: Improved Peptide–MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data , 2017, The Journal of Immunology.

[21]  X. Mariette,et al.  Characterization of CD4 T Cell Epitopes of Infliximab and Rituximab Identified from Healthy Donors , 2017, Front. Immunol..

[22]  S. Stevanović,et al.  Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry , 2018, Immunology.

[23]  Morten Nielsen,et al.  Computational Tools for the Identification and Interpretation of Sequence Motifs in Immunopeptidomes , 2018, Proteomics.

[24]  Morten Nielsen,et al.  Footprints of antigen processing boost MHC class II natural ligand predictions , 2018, Genome Medicine.

[25]  S. Vermeire,et al.  Immunogenicity of biologics in inflammatory bowel disease , 2018, Therapeutic advances in gastroenterology.

[26]  J. Greenbaum,et al.  Improved methods for predicting peptide binding affinity to MHC class II molecules , 2018, Immunology.

[27]  S. Stevanović,et al.  Purification and Identification of Naturally Presented MHC Class I and II Ligands. , 2019, Methods in molecular biology.

[28]  George Coukos,et al.  Robust prediction of HLA class II epitopes by deep motif deconvolution of immunopeptidomes , 2019, Nature Biotechnology.

[29]  Massimo Andreatta,et al.  NNAlign_MA; semi-supervised MHC peptidome deconvolution for accurate characterization of MHC binding motifs and improved T cell epitope prediction , 2019 .

[30]  Jennifer G. Abelin,et al.  Defining HLA-II Ligand Processing and Binding Rules with Mass Spectrometry Enhances Cancer Epitope Prediction. , 2019, Immunity.

[31]  Russ B. Altman,et al.  Predicting HLA class II antigen presentation through integrated deep learning , 2019, Nature Biotechnology.

[32]  M. Nielsen,et al.  NNAlign_MA; MHC Peptidome Deconvolution for Accurate MHC Binding Motif Characterization and Improved T-cell Epitope Predictions. , 2019, Molecular & cellular proteomics : MCP.

[33]  Morten Nielsen,et al.  Improved prediction of MHC II antigen presentation through integration and motif deconvolution of mass spectrometry MHC eluted ligand data. , 2020, Journal of proteome research.